Pharma BD Deal Intelligence

Grifols S.A. / Novartis Diagnostics (blood transfusion unit)

2013 · Asset Purchase · $1.7B · Complete

Announcement Sentiment

Strongly positive

Grifols agreed to acquire Novartis's blood-transfusion diagnostics unit for $1.675B; expected to bring Grifols Diagnostic Division to >20% of company sales (~$1B turnover).

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced Nov 11, 2013
Closed Jan 09, 2014
Deal value $1.7B
Deal type Asset Purchase
Therapeutic area Transfusion medicine / blood screening diagnostics
Indications Transfusion medicine / blood screening diagnostics
Key assets NAT-based blood-screening assays (Procleix), donor screening immunoassays
Mechanism Nucleic acid testing for HIV, HCV, HBV, WNV in blood/plasma donors

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals